DB Power and LPA announce strategic partnership to globally expand solutions for issuers of structured retail products

Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

02005 SSY GROUP

Closed Add to Porfolio
Index Constituent : HS Composite Index, HS Comp. L & M Index, HS Comp. MidCap Ind, HS Comp. M & S Index, Stock Connect HK Ind, Stock Connect HK MS
Major Shareholders Qu Jiguang & Associates (39.84%)
Sichuan Kelun Pharmaceutical Co., Ltd. (21.43%)
UBS Group AG (6.04%)		 Sector Health Care & Biotechnology
Web Site http://www.ssygroup.com.hk Tel (852) 2688-0869
Email henrychow@ssygroup.com.hk Fax (852) 2787-3338
Related Equities N/A
Principal Activities Principally engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, which includes finished medicines, bulk pharmaceuticals and medical materials. The Group has manufacturing plants in Hebei Province and Jiangsu Province, the People’s Republic of China (the “PRC”), and sells to customers mainly in the PRC.

Consolidated List of Substantial Shareholders

Name Number of Shares Interested % of Issued Share Capital (%) Date of Last Notice Filed (Y/M/D)
曲繼廣 1,019,304,000(L)  33.82(L)  03/01/2019
四川科倫藥業股份有限公司 578,084,000(L)  19.45(L)  24/01/2018
四川科倫藥業股份有限公司 512,624,000(L)  18.05(L)  07/07/2017
UBS Group AG 182,324,269(L)  6.05(L)  02/01/2019
Last Update : 2019-02-28
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool

Complete List of Directors

Director's Name Number of Shares Interested % of issued share capital (%) Date of Last Notice Filed (Y/M/D)
曲繼廣 1,019,304,000(L)  33.82(L)  03/01/2019
Last Update : 2019-02-28
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool
Back to Top